Olsen R W, Yang J, King R G, Dilber A, Stauber G B, Ransom R W
Life Sci. 1986 Nov 24;39(21):1969-76. doi: 10.1016/0024-3205(86)90320-6.
The inhibitory neurotransmitter gamma-aminobutyric acid (GABA) acts primarily on receptors that increase chloride permeability in postsynaptic neurons. These receptors are defined by sensitivity to the agonist muscimol and the antagonist bicuculline, and are also subject to indirect allosteric inhibition by picrotoxin-like convulsants and enhancement by the clinically important drugs, the benzodiazepines and the barbiturates. All of these drugs modulate GABA-receptor regulated chloride channels at the cellular level assayed by electrophysiological or radioactive ion tracer techniques. Specific receptor sites for GABA, benzodiazepines, picrotoxin/convulsants, and barbiturates can be assayed in vitro by radioactive ligand binding. Mutual chloride-dependent allosteric interactions between the four receptor sites indicate that they are all coupled in the same membrane macromolecular complex. Indirect effects of barbiturates on the other three binding sites define a pharmacologically specific, stereospecific receptor. All of the activities can be solubilized in the mild detergent 3-[(3-cholamidopropyl)-dimethylammonio]propane sulfonate (CHAPS) and co-purify as a single protein complex.
抑制性神经递质γ-氨基丁酸(GABA)主要作用于能增加突触后神经元氯离子通透性的受体。这些受体通过对激动剂蝇蕈醇和拮抗剂荷包牡丹碱的敏感性来定义,同时也受到类印防己毒素惊厥剂的间接变构抑制以及临床上重要药物苯二氮䓬类和巴比妥类药物的增强作用。所有这些药物在通过电生理或放射性离子示踪技术测定的细胞水平上调节GABA受体调控的氯离子通道。GABA、苯二氮䓬类、印防己毒素/惊厥剂和巴比妥类药物的特异性受体位点可通过放射性配体结合在体外进行测定。四个受体位点之间相互依赖氯离子的变构相互作用表明它们都偶联在同一膜大分子复合物中。巴比妥类药物对其他三个结合位点的间接作用定义了一种药理学特异性、立体特异性受体。所有这些活性都可以在温和去污剂3-[(3-胆酰胺丙基)-二甲基铵]丙烷磺酸盐(CHAPS)中溶解,并作为单一蛋白质复合物共同纯化。